Previous 10 | Next 10 |
LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the closing of the previously announced sale of its CMC-focused German subsidiary, Freeline Therapeutics GmbH, along with certain related intellectual property, to Ascend Gene and Cell ...
Regulated information. This press release contains inside information within the meaning of Regulation (EU) no 596/2014 of the European Parliament and the Council of 16 April 2014 on market abuse (Market Abuse Regulation). Frontline plc (“Frontline”) (NYSE: FRO – OSE: FRO...
LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on January 31, 2023, the Company granted two newly hired employees non-statutory options to purchase an aggregate of 81,000 of the Company’s ordinary shares. The awards ...
Regulated information. This press release contains inside information within the meaning of Regulation (EU) no 596/2014 of the European Parliament and the Council of 16 April 2014 on market abuse (Market Abuse Regulation). Frontline plc (“Frontline”) (NYSE: FRO – OSE: F...
Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs FLT190 currently being investigated in MARVEL-1 Phase 1/2 clinical trial LONDON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Freeline ...
Regulated information. This press release contains inside information within the meaning of Regulation (EU) no 596/2014 of the European Parliament and the Council of 16 April 2014 on market abuse (Market Abuse Regulation). Frontline plc (“Frontline”) (NYSE: FRO – OSE: F...
Regulated information. This press release contains inside information within the meaning of Regulation (EU) no 596/2014 of the European Parliament and the Council of 16 April 2014 on market abuse (market abuse regulation). This notice relates to an earlier notice in accordance with article ...
Regulated information. This press release contains inside information within the meaning of Regulation (EU) no 596/2014 of the European Parliament and the Council of 16 April 2014 on market abuse (Market Abuse Regulation). Frontline plc (“Frontline”) (NYSE: FRO – OSE: F...
LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on December 30, 2022, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 48,900 of the Company’s ordinary shares. The awa...
LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that it received approval from the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of its Americ...
News, Short Squeeze, Breakout and More Instantly...
Freeline Therapeutics Holdings plc Company Name:
FRLN Stock Symbol:
NASDAQ Market:
Freeline Therapeutics Holdings plc Website:
Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline’s GBA1 Parkinson’s disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the...
BioHarvest Sciences Inc (CNVCF) is expected to report for quarter end 2023-12-31 QS Energy Inc (QSEP) is expected to report for Q4 2023 NKGen Biotech Inc. (NKGN) is expected to report for Q4 2023 Cal-Maine Foods Inc. (CALM) is expected to report for Q3 2024 Davide Campari (DVDCF) ...
Please find enclosed the presentation of Frontline plc´s fourth quarter 2023 results to be held on the webcast / conference call 29 February, 2024 at 15:00 CET. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act ...